CX516 (Ampalex®) ( DrugBank: CX516 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00054730 (ClinicalTrials.gov) | June 2002 | 7/2/2003 | Effects of CX516 on Functioning in Fragile X Syndrome and Autism | Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism | Fragile X Syndrome;Autism | Drug: CX516 (Ampalex®) | Cortex Pharmaceuticals | FRAXA Foundation | Completed | 18 Years | 50 Years | Both | Phase 2 | United States |